Inventage Lab인벤티지랩
389470 · KOSDAQ · ₩389470 · 인벤티지랩
₩22,100▼ ₩900 (3.91%)End-of-day · Oct 30, 2026 · End-of-day prices.
Filings
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청) (세마글루타이드 장기지속형 주사제 IVL3021의 호주 제1상 임상시험계획 승인 신청)Oct 28, 2026Open on DART
Predicted impact: Low
Clinical trial plan approval application for an early-stage drug is routine and small in impact.
- Adjustment of Conversion Price for Convertible Shares (Convertible Preferred Shares)전환주식의전환가액조정 (전환우선주)Oct 19, 2026Open on DART
Predicted impact: Low
Routine conversion price adjustment on preferred shares; no new share count given.
- Investor relations (IR) event기업설명회(IR)개최Sep 15, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 26, 2026Open on DART
- Other management matters기타경영사항(자율공시) ([국책과제 선정] 2026년도 투·융자 연계 기술개발 정책지정형 글로벌 팁스 (미세유체 기술을 적용한 글로벌 임상1상 결과를 기반한 약물중독 치료용 장기지속형 주사제의 글로벌 후기 임상 개발 및 사업화))Aug 3, 2026Open on DART
- Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Jul 24, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jun 29, 2026Open on DART
- Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) Before Maturity After Issuance (2nd Series)전환사채(해외전환사채포함)발행후만기전사채취득 (제2회차)Jun 22, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jun 16, 2026Open on DART
- Material Matters Report (Decision on Acquisition of Own Convertible Bonds Before Maturity)주요사항보고서(자기전환사채만기전취득결정)Jun 15, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Jun 8, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jun 5, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)Jun 1, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서May 8, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서May 8, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서May 8, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험결과) (건강한 성인을 대상으로 IVL3003의 피하 또는 근육 주사와 ARICEPT®(도네페질) 정제 반복 투여 간 비교를 위한 공개, 탐색적, 연속적, 약동학, 단일용량상승 1상 임상시험)Apr 20, 2026Open on DART
- Capital reduction decision감자결정(종속회사의주요경영사항)Apr 14, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Apr 13, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Apr 13, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Apr 7, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Apr 2, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 31, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 31, 2026Open on DART
- Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Mar 31, 2026Open on DART
- Audit report submitted감사보고서제출Mar 23, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 23, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최Mar 19, 2026Open on DART
- Amended: Rights offering (paid-in capital increase) decision[기재정정]주요사항보고서(유상증자결정)Mar 17, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 17, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Mar 16, 2026Open on DART
- Change in Revenue or Profit/Loss Structure of 30% or More (15% or More for Large Companies)매출액또는손익구조30%(대규모법인은15%)이상변동Mar 16, 2026Open on DART
- Securities Issuance Results (Voluntary Disclosure) (Third-Party Allotment Rights Offering - Convertible Preferred Shares)증권발행결과(자율공시) (제3자배정유상증자-전환우선주)Mar 16, 2026Open on DART
- Securities Issuance Results (Voluntary Disclosure) (5th Bond with Warrants)증권발행결과(자율공시) (5BW)Mar 16, 2026Open on DART
- Securities Issuance Results (Voluntary Disclosure) (4th Convertible Bonds)증권발행결과(자율공시) (4CB)Mar 16, 2026Open on DART
- Rights offering (paid-in capital increase) decision주요사항보고서(유상증자결정)Mar 9, 2026Open on DART
- Acquisition of shares in another company타법인주식및출자증권취득결정(자율공시)Mar 6, 2026Open on DART
- Bond with warrants issue decision주요사항보고서(신주인수권부사채권발행결정)Mar 6, 2026Open on DART
- Convertible bond issue decision주요사항보고서(전환사채권발행결정)Mar 6, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청등결정) (성인 안드로겐 탈모 남성에서 IVL3001의 유효성, 약동/약력학적 특성 및 안전성을 평가하기 위한 무작위배정, 공개, 평행 설계 2상 임상시험을 위한 호주 IND 계획 승인)Feb 27, 2026Open on DART
- Acquisition of shares in another company타법인주식및출자증권취득결정Feb 26, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Feb 6, 2026Open on DART
- [Amended] Exercise of Conversion Rights (1st Series)[기재정정]전환청구권행사 (제1회차)Feb 4, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Feb 4, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Feb 4, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Feb 4, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Feb 4, 2026Open on DART
- Exercise of Conversion Rights (1st Series)전환청구권행사 (제1회차)Jan 23, 2026Open on DART
- [Attached Correction] Major Matters Report (Decision on Sale of Treasury Convertible Bonds)[첨부정정]주요사항보고서(자기전환사채매도결정)Jan 22, 2026Open on DART
- Material Matters Report (Sale of Own Convertible Bonds Decision)주요사항보고서(자기전환사채매도결정)Jan 22, 2026Open on DART
Titles in Korean until English translations are added.
Also known as: Inventage Lab / 인벤티지랩 / 389470 / KRX:389470
Source: KRX statistical information